| Literature DB >> 22666488 |
Octavio P Luzardo1, Luis Alberto Henríquez-Hernández, Pilar F Valerón, Pedro C Lara, Maira Almeida-González, Antonio Losada, Manuel Zumbado, Lluis Serra-Majem, Eva Elisa Alvarez-León, Luis D Boada.
Abstract
OBJECTIVE: Insulin-like growth factor I (IGF-I) and dioxin-like polychlorobiphenyls (DL-PCBs) have been associated with the pathogenesis of several diseases like cancer, diabetes and growth disorders. Because it has been suggested that organohalogenated contaminants could influence IGF-I levels in adults, the potential relationship between DL-PCBs and IGF-I serum levels was studied in 456 healthy adults from a representative sample of the general population of the Canary Islands (Spain).Entities:
Mesh:
Substances:
Year: 2012 PMID: 22666488 PMCID: PMC3362561 DOI: 10.1371/journal.pone.0038213
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Biological characteristics of the studied population, N (%).
| Characteristic | Total | Male | Female |
| 456 (100) | 203 (44.5) | 253 (55.5) | |
|
| |||
|
| 107 (17.6) | 47 (23.2) | 60 (23.7) |
|
| 139 (22.9) | 57 (28.1) | 82 (32.4) |
|
| 141 (23.2) | 64 (31.5) | 77 (30.4) |
|
| 69 (11.4) | 35 (17.2) | 34 (13.5) |
|
| |||
|
| 10 (2.3) | 3 (1.5) | 7 (2.9) |
|
| 164 (35.9) | 72 (35.4) | 92 (36.4) |
|
| 175 (38.4) | 79 (39.0) | 96 (38.0) |
|
| 107 (23.4) | 49 (24.1) | 58 (22.7) |
Distribution of IGF-I and IGFBP-3 (ng/ml) in the studied population.
| Characteristic | IGF-I[median (p5-p95)] | IGFBP-3[median (p5-p95)] |
|
| 157.0 (73.0–277.5) | 3998.0 (2607.0–5775.0) |
|
| ||
| Male | 159.0 (87.0–278.0) | 3938.0 (2427.8–5853.6) |
| Female | 155.5 (70.9–273.4) | 4044.0 (2835.2–5770.8) |
|
| 0.428 | 0.025 |
|
| ||
| 18–34 | 201.0 (125.2–320.8) | 4205.5 (3094.4–6067.4) |
| 35–50 | 170.0 (101.6–246.4) | 4074.0 (2918.3–5912.0) |
| 50–65 | 145.0 (64.3–237.5) | 3763.0 (2318.5–5528.7) |
| >65 | 133.0 (39.0–227.0) | 3588.0 (2286.9–5260.5) |
|
| <0.001 | <0.001 |
|
| ||
| <18.5 | 210.0 (113.0–307.0) | 4814.5 (3110.0–5410.0) |
| 18.5–24.99 | 178.0 (100.4–304.8) | 3939.0 (2627.3–5825.1) |
| 25–29.99 | 151.0 (83.4–263.3) | 3998.0 (2563.8–5543.6) |
| >30 | 140.0 (57.7–243.6) | 3978.0 (2470.8–5952.0) |
|
| <0.001 | 0.135 |
Abbreviations: p5 represents the 5th percentile and p95 represents the 95th percentile.
P values correspond to comparison between characteristics, for IGF-I and IGFBP-3 (Kruskal-Wallis test).
Distribution of DL-PCBs concentrations (ng/g lipid) and TEQs (pg/g lipid) in adult blood serum in the population of the Canary Islands.
| Congener | Concentration median (p5–p95) | TEQs median(p5–p95) | (%) |
|
| |||
|
| <LOQ | N.A. | 0.0 |
|
| 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 4.6 |
|
| 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.7 |
|
| 0.0 (0.0–1.3) | 0.0 (0.0–38.9) | 6.1 |
|
| |||
|
| <LOQ | N.A. | 0.0 |
|
| <LOQ | N.A. | 0.0 |
|
| 0.0 (0.0–23.1) | 0.1 (0.0–0.7) | 18.9 |
|
| 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.9 |
|
| 0.0 (0.0–10.9) | 0.0 (0.0–0.3) | 48.5 |
|
| 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.2 |
|
| 0.0 (0.0–8.7) | 0.0 (0.0–0.3) | 43.9 |
|
| 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 1.5 |
|
| 2.8 (0.0–56.8) | 60.3 | |
|
| 0.0 (0.0–0.4) | 0.1 (0.0–40.2) | 60.9 |
Abbreviations: LOQ, limit of quantification; N.A., not applicable. p5 and p95 represent the 5th and 95th percentiles respectively. ∑DL-PCB: sum over the dioxin-like PCB levels (IUPAC numbers 77, 81, 105, 114, 118, 123, 126, 156, 157, 167, 169, and 189). ∑TEQs: sum over TEQs for the DL-PCBs.
Figure 1Scatter plot of log IGF-I serum levels and log of DL-PCB 156 (A), PCB 167 (B), ∑DL-PCBs (C), and ∑TEQs serum levels (D).
Arithmetic means and their 95% confidence intervals (95% CIs) of IGF-I (ng/ml) by serum levels of DL-PCB 156 (ng/g lipid), ∑DL-PCB (ng/g lipid) and ∑TEQs (pg/g lipid) in women, according to age and BMI categories.
| Women (18–46) | Women (>46) | ||||||||
| N | BMI (<27)IGF-I mean (95%CI) | N | BMI (>27)IGF-I mean (95%CI) | N | BMI (<27)IGF-I mean (95%CI) | N | BMI (>27)IGF-I mean (95%CI) | ||
| DL-PCB 156 | ND | 43 | 215.2 (199.0–231.3) | 11 | 181.9 (146.6–217.1) | 14 | 168.1 (140.8–195.4) | 34 | 144.3 (126.1–162.5) |
| D | 24 | 170.0 (148.4–191.7) | 13 | 166.1 (133.7–198.4) | 26 | 142.5 (122.6–162.5) | 37 | 130.7 (113.3–148.1) | |
|
| 0.001 | ns | ns | ns | |||||
| ∑DL-PCB | T1 | 32 | 219.2 (200.1–238.4) | 10 | 186.1 (148.1–224.1) | 8 | 158.5 (121.1–195.8) | 27 | 136.5 (116.1–156.7) |
| T2 | 21 | 183.8 (160.1–207.5) | 8 | 164.4 (119.6–209.2) | 15 | 155.3 (127.6–183.0) | 18 | 153.7 (128.8–178.6) | |
| T3 | 14 | 175.7 (146.7–204.8) | 6 | 163.9 (115.4–212.4) | 17 | 144.8 (118.6–170.9) | 26 | 126.6 (105.9–147.3) | |
|
| 0.017 | ns | ns | ns | |||||
| ∑TEQs | T1 | 32 | 219.2 (200.1–238.4) | 10 | 185.0 (147.3–222.7) | 8 | 158.5 (121.1–195.8) | 27 | 136.5 (116.1–156.7) |
| T2 | 21 | 180.9 (157.2–204.6) | 9 | 172.2 (129.8–214.7) | 15 | 155.3 (127.6–183.0) | 19 | 153.2 (129.0–177.5) | |
| T3 | 14 | 179.9 (150.9–209.0) | 5 | 151.9 (98.2–205.5) | 17 | 144.8 (118.6–170.9) | 25 | 125.8 (104.7–146.9) | |
|
| 0.019 | ns | ns | ns | |||||
Adjusted means of IGF values were obtained by variance component analysis. IGFBP-3 and age or BMI were included in the model as cofounding factors. T1: first tertile of the distribution; T2: second tertile of distribution; T3: third tertile of the distribution; ND: non-detectable; D: detectable; ns: non-significant.